EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer
Abstract
Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, 18F-EF5, is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2013
- Accession Number
- ADA594308
Entities
People
- Billy W. Loo Jr.
Organizations
- Stanford University